{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T04:47:56Z","timestamp":1774500476205,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Immunological Methods"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jim.2024.113710","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T16:20:17Z","timestamp":1718122817000},"page":"113710","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Development of an immunoassay for quantification of soluble human CD40L (CD154) in plasma and serum samples"],"prefix":"10.1016","volume":"531","author":[{"given":"Kathrine","family":"Pedersen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick Stub","family":"Laursen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette Gudmann","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaseelan","family":"Palarasah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jim.2024.113710_bb0005","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/mab.2018.0024","article-title":"Novel monoclonal antibodies against native human Collectin L1, using the Heteromeric complex CL-LK as immunogen","volume":"37","author":"Aagaard","year":"2018","journal-title":"Monoclon. Antib. Immunodiagn. Immunother."},{"key":"10.1016\/j.jim.2024.113710_bb0010","doi-asserted-by":"crossref","first-page":"22342","DOI":"10.3390\/ijms151222342","article-title":"The signaling role of CD40 ligand in platelet biology and in platelet component transfusion","volume":"15","author":"Aloui","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jim.2024.113710_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2020.112807","article-title":"Facile generation of monoclonal antibodies suitable for conjugation","volume":"483","author":"Bjerrum","year":"2020","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jim.2024.113710_bb0020","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1084\/jem.185.12.2053","article-title":"A new mechanism of NK cell cytotoxicity activation: the CD40-CD40 ligand interaction","volume":"185","author":"Carbone","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jim.2024.113710_bb0025","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1038\/d41591-023-00060-4","article-title":"Anti-CD40L antibody frexalimab slows new brain lesions in multiple sclerosis","volume":"29","author":"Carvalho","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.jim.2024.113710_bb0030","series-title":"Quantifications of Western Blots with ImageJ","author":"Davarinejad","year":"2024"},{"key":"10.1016\/j.jim.2024.113710_bb0035","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1172\/JCI118643","article-title":"Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production words: system lupus erythematosus \u2022 anti-DNA autoanti-bodies \u2022 autoimmune disease \u2022 CD40 ligand expression \u2022 im-munotherapy","volume":"97","author":"Desai-Mehta","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jim.2024.113710_bb0040","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","article-title":"Molecular mechanism and function of CD40\/CD40L engagement in the immune system","volume":"229","author":"Elgueta","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jim.2024.113710_bb0045","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jim.2006.07.001","article-title":"Quantification of mannan-binding lectin","volume":"315","author":"Frederiksen","year":"2006","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jim.2024.113710_bb0050","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","article-title":"Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus","volume":"60","author":"Furie","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.jim.2024.113710_bb0055","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1002\/eji.1830250639","article-title":"A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation","volume":"25","author":"Graf","year":"1995","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jim.2024.113710_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12985-021-01680-3","article-title":"Platelet-derived sCD40L: specific inflammatory marker for early-stage severe acute respiratory syndrome coronavirus 2 infection","volume":"18","author":"Hamzeh-Cognasse","year":"2021","journal-title":"Virol. J."},{"key":"10.1016\/j.jim.2024.113710_bb0065","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1182\/blood-2012-05-427799","article-title":"Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role","volume":"120","author":"Huang","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jim.2024.113710_bb0070","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1046\/j.1468-1331.2001.00232.x","article-title":"Increased T cell expression of CD154 (CD40-ligand) in multiple sclerosis","volume":"8","author":"Jensen","year":"2001","journal-title":"Eur. J. Neurol."},{"issue":"256","key":"10.1016\/j.jim.2024.113710_bb0075","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"2565517","author":"K\u00f6hler","year":"1975","journal-title":"Nat"},{"key":"10.1016\/j.jim.2024.113710_bb0080","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.44245","article-title":"The quantity of CD40 signaling determines the differentiation of B cells into functionally distinct memory cell subsets","volume":"8","author":"Koike","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.jim.2024.113710_bb0085","doi-asserted-by":"crossref","first-page":"9447","DOI":"10.1007\/s13277-014-2407-x","article-title":"Multifunctional CD40L: pro- and anti-neoplastic activity","volume":"35","author":"Korniluk","year":"2014","journal-title":"Tumour Biol."},{"key":"10.1016\/j.jim.2024.113710_bb0090","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1172\/JCI118855","article-title":"Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes","volume":"98","author":"Koshy","year":"1996","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.jim.2024.113710_bb0095","first-page":"1","article-title":"Cell-specific and divergent roles of the CD40L-CD40 axis in atherosclerotic vascular disease","volume":"121","author":"Lacy","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jim.2024.113710_bb0100","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/j.ijcard.2013.03.019","article-title":"Artifactual elevation of plasma sCD40L by residual platelets in patients with coronary artery disease","volume":"168","author":"Lee","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.jim.2024.113710_bb0105","doi-asserted-by":"crossref","first-page":"R97","DOI":"10.1186\/cc10104","article-title":"Association between serum soluble CD40 ligand levels and mortality in patients with severe sepsis","volume":"15","author":"Lorente","year":"2011","journal-title":"Crit. Care"},{"key":"10.1016\/j.jim.2024.113710_bb0110","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jneuroim.2017.01.024","article-title":"Soluble CD40 ligand contributes to blood\u2013brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder","volume":"305","author":"Masuda","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jim.2024.113710_bb0115","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3109\/07853890.2010.546362","article-title":"The CD40-CD40L system in cardiovascular disease","volume":"43","author":"Pamukcu","year":"2011","journal-title":"Ann. Med."},{"key":"10.1016\/j.jim.2024.113710_bb0120","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.4049\/jimmunol.163.3.1123","article-title":"Cutting edge: CD40 ligand is a limiting factor in the humoral response to T cell-dependent antigens","volume":"163","author":"P\u00e9rez-Melgosa","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.jim.2024.113710_bb0125","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.smim.2009.05.012","article-title":"CD40 and autoimmunity: the dark side of a great activator","volume":"21","author":"Peters","year":"2009","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.jim.2024.113710_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102668","article-title":"Phoenix from the flames: rediscovering the role of the CD40\u2013CD40L pathway in systemic lupus erythematosus and lupus nephritis","volume":"19","author":"Ramanujam","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jim.2024.113710_bb0135","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10238-019-00568-5","article-title":"Assessment of CD40 and CD40L expression in rheumatoid arthritis patients, association with clinical features and DAS28","volume":"19","author":"Rom\u00e1n-Fern\u00e1ndez","year":"2019","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.jim.2024.113710_bb0140","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1158\/1078-0432.CCR-0348-03","article-title":"Soluble CD40 ligand plasma levels in lung Cancer","volume":"10","author":"Roselli","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jim.2024.113710_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.exger.2021.111677","article-title":"Analysis of physical activity and plasma levels of soluble CD40 and CD40L in older people with gastrointestinal tract cancer","volume":"160","author":"Silva","year":"2022","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.jim.2024.113710_bb0150","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1042\/CS20060047","article-title":"Influence of pre-analytical and analytical factors on soluble CD40L measurements","volume":"111","author":"Varo","year":"2006","journal-title":"Clin. Sci."},{"key":"10.1016\/j.jim.2024.113710_bb0155","series-title":"The Role of CD40 Ligand in Systemic Lupus Erythematosus","first-page":"377","volume":"13","author":"Yazdany","year":"2004"}],"container-title":["Journal of Immunological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175924000954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175924000954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T13:10:21Z","timestamp":1720617021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022175924000954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":31,"alternative-id":["S0022175924000954"],"URL":"https:\/\/doi.org\/10.1016\/j.jim.2024.113710","relation":{},"ISSN":["0022-1759"],"issn-type":[{"value":"0022-1759","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of an immunoassay for quantification of soluble human CD40L (CD154) in plasma and serum samples","name":"articletitle","label":"Article Title"},{"value":"Journal of Immunological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jim.2024.113710","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113710"}}